Skip to content
Winnowleaf home

Peptide

Telavancin (Vibativ)

Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP). ATLAS trials (n=1794): Clinical cure 88.3% vs 87.1% vancomycin (noninferior) for cSSSI. ATTAIN trials: Approved for hospital-acquired pneumonia when alternatives not suitable. Coverage: MRSA, MSSA, Streptococci, E. faecalis. SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment; use when alternatives not suitable.

Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.

Best evidence
Grade A
Conditions studied
2
Outcomes
7
Graded outcomes
4030

Evidence by condition

  • Strong
  • Moderate
  • Limited
  • Very limited

2 conditions, plus general outcomes

Skin and Soft Tissue Infections

Skin and Soft Tissue Infections: outcomes studied for Telavancin (Vibativ)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Clinical Cure Rate - cSSSI

ATLAS-1 & ATLAS-2 Phase 3 (n=1794): Clinical cure rate 88.3% telavancin vs 87.1% vancomycin in clinically evaluable patients. Noninferior to vancomycin for complicated skin and skin structure infections including MRSA.

NoneNo effect7 studies

Studies that measured clinical cure rate - csssi

Nephrotoxicity Risk

SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment (CrCl <50 mL/min). Avoid in moderate-severe renal impairment unless benefit outweighs risk. Monitor renal function closely. Dose adjust for CrCl <50.

Worsens (the measure goes up)Moderate effect5 studies

Studies that measured nephrotoxicity risk

Acute Respiratory Infection (ARI)

Acute Respiratory Infection (ARI): outcomes studied for Telavancin (Vibativ)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Hospital-Acquired Pneumonia Efficacy

ATTAIN-1 & ATTAIN-2 Phase 3: Clinical cure rates comparable to vancomycin for S. aureus HABP/VABP. FDA-approved June 2013 but indicated only when alternative treatments not suitable due to safety concerns.

NoneNo effect6 studies

Studies that measured hospital-acquired pneumonia efficacy

Mortality in Renal Impairment

SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials. Telavancin should only be used when alternatives not suitable. Risk-benefit assessment required.

Worsens (the measure goes up)Moderate effect5 studies

Studies that measured mortality in renal impairment

General

General: outcomes studied for Telavancin (Vibativ)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Antimicrobial Activity

18 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.

Improves (the measure goes up)Moderate effect11 studies

Studies that measured antimicrobial activity

and 1 more in the citations list

Kidney Function

4 human trials support this finding. Human clinical trial data available.

Improves (the measure goes up)Small effect6 studies

Studies that measured kidney function

Safety/Tolerability

4 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.

Improves (the measure goes up)Small effect5 studies

Studies that measured safety/tolerability

Key findings

  • Clinical Cure Rate - cSSSISkin and Soft Tissue Infections
  • Hospital-Acquired Pneumonia EfficacyAcute Respiratory Infection (ARI)
  • Nephrotoxicity RiskSkin and Soft Tissue InfectionsWorsens (the measure goes up)

Safety notes in the studies

  • Avoid in moderate-severe renal impairment unless benefit outweighs risk.
  • SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials.
  • Risk-benefit assessment required.

Studies cited

23 studies from PubMed

  1. Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis.Antibiotics (Basel, Switzerland), 2024 · PMID 39335039
  2. Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2-17 years of age.Antimicrobial agents and chemotherapy, 2023 · PMID 37815398
  3. Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.The Journal of antimicrobial chemotherapy, 2021 · PMID 34613416
  4. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.Journal of global antimicrobial resistance, 2020 · PMID 31325617
  5. Renal Dosing of Antibiotics: Are We Jumping the Gun?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019 · PMID 30219824
  6. Telavancin-associated acute kidney injury
.Clinical nephrology, 2019 · PMID 30614441
  7. A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: A meta-analysis.International journal of clinical pharmacology and therapeutics, 2017 · PMID 28793957
  8. Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Frontiers in pharmacology, 2016 · PMID 27721793
  9. Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infectionsExpert Rev Anti Infect Ther, 2015 · PMID 26059192
  10. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015 · PMID 26316560
  11. Telavancin: a systematic review of the clinical evidenceTher Adv Infect Dis, 2014 · PMID 22916113
  12. Glycopeptide antibiotic biosynthesis.The Journal of antibiotics, 2014 · PMID 24220108
  13. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.Expert review of anti-infective therapy, 2014 · PMID 25382700
  14. Frontline antibiotic therapy.Clinical medicine (London, England), 2013 · PMID 23760700
  15. Stability and compatibility of antimicrobial lock solutions.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013 · PMID 24296841
  16. Telavancin: a review of its use in patients with nosocomial pneumonia.Drugs, 2013 · PMID 24190596
  17. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adultsClin Ther, 2011 · PMID 21316534
  18. Lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancinDrugs, 2010 · PMID 20030476
  19. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.Infectious disease clinics of North America, 2009 · PMID 19909893
  20. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.The International journal of artificial organs, 2009 · PMID 19943236
  21. Telavancin: a novel lipoglycopeptide antibioticAnn Pharmacother, 2008 · PMID 19401479
  22. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.Pharmacotherapy, 2008 · PMID 18363530
  23. Telavancin: a novel lipoglycopeptide antimicrobial agent.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007 · PMID 17989443